This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).
Clinical trial NCT03713619 · COMPLETED
Trial details
- NCT number
- NCT03713619
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-31
- Primary completion
- 2021-10-01
- Enrollment
- 544
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.